Stock listing

Stockholm:INIT Initiator Pharma A/S Aktie

Follow Initiator Pharma A/S into a list and get an email when it puts out news.

Share price · OMXSTO:INIT

2.50 SEK -0.07 (-2.7%)

Close on Nov 20, 2026

Past year -10.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
2.46 – 2.62 SEKNov 20, 2026
Volume
50,477 sharesNov 20, 2026
Market cap
171.1M SEKAt the close on Nov 20, 2026 · price × 68.45M shares outstanding
52-week range
1.67 – 3.65 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
364,131 SEKMedian day 123,064 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Initiator Pharma A/S logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:INIT · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
2.50-0.07-2.7%2.472.622.4650,477
2.57+0.16+6.6%2.412.642.391,401,672
2.41-0.28-10.4%2.692.692.41218,457
2.69+0.42+18.5%2.352.802.27154,910
2.27-0.03-1.3%2.382.422.22250,551
2.30-0.19-7.6%2.592.592.28159,757
2.49+0.31+14.2%2.512.542.40129,930
2.18+0.03+1.4%2.192.492.10211,412
2.15+0.18+9.1%1.952.271.865198,526
1.97+0.165+9.1%1.811.9751.8150,656
1.805-0.005-0.3%1.8551.9851.755110,350
1.81-0.135-6.9%1.9151.9151.8196,523
1.945-0.145-6.9%1.991.9951.88546,235
2.09+0.04+2.0%2.012.291.875258,490
2.05-0.12-5.5%2.172.221.715802,710
2.17-0.07-3.1%2.242.322.1047,337
2.24-0.13-5.5%2.332.362.19126,103
2.37+0.13+5.8%2.382.492.2464,308
2.240.000.0%2.292.292.1542,060
2.24-0.08-3.4%2.212.382.2066,084
2.32+0.02+0.9%2.242.322.1685,473
2.30+0.21+10.0%2.202.302.13149,330
2.09+0.03+1.5%1.9052.091.90558,941
2.06+0.065+3.3%2.082.201.925159,439
1.995-0.145-6.8%2.232.231.925183,755
2.14+0.145+7.3%2.102.162.05120,389
1.995+0.195+10.8%1.851.9951.8598,019
1.80+0.03+1.7%1.771.8951.7729,987
1.77+0.025+1.4%1.7251.771.66595,479
1.745-0.12-6.4%1.8951.8951.705156,097
1.865-0.10-5.1%1.9151.961.835179,079
1.965-0.065-3.2%1.992.051.91564,900
2.03+0.03+1.5%1.9952.061.9614,528
2.00-0.12-5.7%2.112.111.97228,592
2.12+0.10+5.0%1.982.301.815410,646
2.02-0.01-0.5%2.012.081.98216,879
2.03-0.05-2.4%2.142.141.965219,118
2.08-0.06-2.8%2.132.242.07138,983
2.14+0.09+4.4%2.152.152.0199,923
2.05-0.11-5.1%2.232.231.975146,260
2.16-0.03-1.4%2.182.242.10287,956
2.19+0.08+3.8%2.092.252.08209,462
2.11-0.07-3.2%2.222.222.06284,706
2.18-0.06-2.7%2.242.292.11261,474
2.24-0.05-2.2%2.242.332.15233,114
2.29-0.06-2.6%2.362.372.2587,219
2.35-0.09-3.7%2.422.452.3355,363
2.44+0.05+2.1%2.332.442.3321,211
2.39+0.01+0.4%2.382.482.3251,280
2.38-0.10-4.0%2.432.452.32125,738
2.48+0.09+3.8%2.372.482.3446,420
2.390.000.0%2.352.542.35112,276
2.39+0.05+2.1%2.322.412.2977,812
2.34-0.01-0.4%2.412.412.2970,948
2.35+0.04+1.7%2.332.402.3273,826
2.31-0.03-1.3%2.262.342.2634,140
2.34+0.04+1.7%2.302.342.24108,494
2.30-0.05-2.1%2.552.552.27185,689
2.35-0.08-3.3%2.432.432.3423,631
2.43-0.04-1.6%2.482.482.34155,973
2.47-0.03-1.2%2.502.502.39146,682
2.50-0.09-3.5%2.502.662.4299,903
2.59+0.06+2.4%2.542.672.40265,306
2.530.000.0%2.642.652.3764,652
Ticker
Stockholm:INIT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stockholm
Currency
SEK

What changed lately

Latest news

All Initiator Pharma A/S news

Initiator Pharma A/S on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 25 in all · newest Sep 14, 2026 · oldest 2024

Valuation

Price/book 13.4× against a median of 0.9×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
160.0M SEK
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
13.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
1.1×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Initiator Pharma A/S · OMXSTO:INITUS$16.74MUS$15.65Mn/an/an/a13.4×n/a1.1×n/a
Resverlogix Corp. · TSX:RVXUS$18.01MUS$95.55Mn/an/an/an/an/an/a0.26
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Neurotech International Ltd. · ASX:NTIUS$16.63MUS$15.06Mn/an/an/a41.1×n/a0.0×n/a
Akari Therapeutics PLC · NASDAQ:AKTXUS$16.41MUS$10.66Mn/an/an/a0.9×n/a0.0×1.49
Lipocine Inc. · NASDAQ:LPCNUS$16.39M−US$5.07Mn/a−1.4×n/a0.8×−249.2%0.0×1.18
MaaT Pharma · EURONEXT:MAATUS$16.11MUS$23.36Mn/a4.7×n/an/a−686.6%n/an/a
Elicera Therapeutics AB · OMXSTO:ELICUS$16.09MUS$10.40Mn/an/an/a2.9×n/a0.0×n/a
Pasithea Therapeutics Corp. · NASDAQ:KTTAUS$16.00M−US$25.22Mn/an/a−0.1×0.4×n/a0.0×0.97
Atossa Therapeutics, Inc. · NASDAQ:ATOSUS$15.92M−US$4.66Mn/an/an/a0.7×n/a0.0×0.87
Quoin Pharmaceuticals. Ltd · NASDAQ:QNRXUS$15.76M−US$17.43Mn/an/an/a0.6×n/a0.0×0.68
Median of the othersUS$16.25MUS$10.53M4.7×−0.1×0.9×−249.2%0.0×0.92

Forecasts

Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
5.11 SEK · Analysts' mean
EPS, year to Dec 2026
-0.59 · 1 analyst

Team and board

Officers

OfficerRole
Claus Elsborg OlesenCEO and board member
Annette SäfholmChief Operating Business Officer (COO)

Board

DirectorRole
Magnus PerssonChairman of the Board
Annette ColinBoard member
Christina LloydBoard member
Claus Elsborg OlesenCEO and board member
Gunilla EkströmBoard member
Peter HolmBoard member

Events

QuarterResultsShare move
Q4 2025Feb 20, 2026 · Before open−3.9%
Q3 2025Nov 21, 2025 · Before open+1.8%
Q2 2025Aug 22, 2025 · Before open+4.3%
Q1 2025May 9, 2025 · Before open−4.7%
Q4 2024Feb 28, 2025 · Before open0.0%
Q3 2024Nov 29, 2024 · Before open+3.5%
Q2 2024Aug 23, 2024 · Before open0.0%
Q1 2024May 10, 2024 · Before open−0.7%
Q4 2023Feb 23, 2024 · Before open+0.9%
Q3 2023Nov 10, 2023 · Before open+2.9%
All 17 quarters
QuarterResultsShare move
Q2 2023Aug 25, 2023 · Before open+1.4%
Q1 2023May 5, 2023 · Before open+2.2%
Q4 2022Feb 17, 2023 · Before open+0.3%
Q3 2022Nov 4, 2022 · Before open−4.4%
Q2 2022Aug 26, 2022 · Before open−0.3%
Q1 2022May 6, 2022 · Before open0.0%
Q4 2021Feb 18, 2022 · Before open−5.7%

Open Events

Financials

Annual, in DKK

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000
Cost of revenue14.8M11.1K23.4K38.4K21.6K9.30K8.37K11.4K8.18K1.05K
Gross profit-14.8M-11.1K-23.4K-38.4M-21.6K-9.30K-8.37K-11.4K-8.18K-1.05K
Research and development4.19M1.78K15.3K26.3K11.8K5.19K6.26K8.67K6.09K
Selling, general and administrative2.95M3.43M3.62M3.31M1.44M
Operating income-18.2M-14.5K-27.0K-41.7M-23.1K-10.5K-9.34K-12.6K-9.56K-1.33K
Depreciation and amortization211111.0K26.0K87.0K88.0K84.0K12.0K
EBITDA-14.5K-27.0K-41.7M-12.1K15.5K77.7K75.4K74.4K10.7K
Interest expense02.00K3.71M2.39M1.17M291.0K636.0K93.0K801.0K5.00K
Income before tax-17.1M-14.8K-27.7K-44.1M-24.2K-10.2K-9.97K-12.7K-10.4K-1.34K
Income tax-3.08M-1.90K-4.83K-5.68M-3.18K-1.54K-1.69M-2.41M-1.78M12.0K
Net income-14.0M-12.9K-22.9K-38.5M-21.1M-8.70M-8.29M-10.3M-8.58M-892.0K
Earnings per share, basic-0.22-0.23-0.00-795.76-600.32-317.70-341.89-512.82-1,044.17-0.08

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents26.3M13.4M24.1M38.9M34.1M13.5M7.36M14.3M6.97M167.0K
Short-term investments200.0K
Receivables3.33M599.0K1.71M945.0K545.0K2.97M2.71M1.92M
Current assets33.0M15.3M29.8M48.3M53.7M15.6M11.4M17.2M9.09M398.0K
Property, plant and equipment4.00K69.0K134.0K
Total assets33.0M15.3M29.8M48.3M53.7M15.6M11.4M17.3M9.30M563.0K
Accounts payable864.4K366.0K407.0K801.0K4.80M666.0K1.14M239.0K1.42M
Current liabilities1.28M510.0K3.19M1.75M5.42M1.19M1.53M758.0K3.33M934.0K
Long-term debt2.15M015.4M12.6M13.3M0
Total debt2.15M15.4M12.6M13.3M
Total liabilities3.43M510.0K18.6M14.3M18.7M1.19M1.53M758.0K3.33M934.0K
Shareholders' equity29.6M14.8M11.2M34.0M35.0M14.4M9.91M16.6M5.96M-371.0K
Shares outstanding62.3M57.3K52.4M48.3K35.1K27.4K24.2K20.1K8.22K11.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-18.2M-12.1M-17.6M-32.7M-34.1M-8.06M-8.55M-13.6M-7.78M-178.0K
Capital spending-18.2M0000000-132.0K-177.0K
Free cash flow-17.7M-12.1M-17.6M-32.7M-34.1M-8.06M-8.55M-13.6M-7.92M-355.0K
Cash from investing-17.0K-17.0K-17.0K-17.0K-132.0K-177.0K
Cash from financing31.4M1.11M2.87M37.5M54.9M14.0M1.63M20.9M14.9M521.0K
Share buybacks0-690.0K0
Change in cash12.1M-11.0M-14.8M4.77M20.8M5.94M-6.93M7.32M7.00M521.0K

Open Financials

Cap table

Built by 6ix from Initiator Pharma A/S’ releases

Common shares
68,452,892
Fully diluted
68,452,892

Fully diluted

LineShares
Common shares68,452,892

Share count over time

CountShares
Nov 22, 202668,452,892

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Annette ColinBoard member · Since at least May 29, 2026
Annette SäfholmChief Operating Business Officer (COO) · Since at least Sep 14, 2026
Christina LloydBoard member · Since at least May 29, 2026
Claus Elsborg OlesenCEO and board member · Since at least Sep 14, 2026
Gunilla EkströmBoard member · Since at least May 29, 2026
Magnus PerssonChairman of the Board · Since at least May 29, 2026
Peter HolmBoard member · Since at least May 29, 2026

Open People

Log in to ask 6ix AI your own questions about Initiator Pharma A/S.